Phgdh-flox Mouse
一般名
Phgdh-flox
製品ID
S-CKO-07879
背景情報
C57BL/6JCya
系統ID
CKOCMP-236539-Phgdh-B6J-VB
状況
このマウス系統を論文で使用する場合は、「Phgdh-flox Mouse(カタログ番号S-CKO-07879)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Phgdh-flox
系統ID
CKOCMP-236539-Phgdh-B6J-VB
遺伝子名
製品ID
S-CKO-07879
遺伝子別名
A10, PGD, PGAD, PGDH, SERA, 3PGDH, 3-PGDH, 4930479N23
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conditional knockout
染色体
Chr 3
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000065793
NCBIトランスクリプトID
NM_016966
ターゲット領域
Exon 2~3
有効領域の大きさ
~2.8 kb
遺伝子研究の概要
Phgdh, also known as PhosphoGlycerol Dehydrogenase, is the first rate-limiting enzyme in the serine biosynthesis pathway, catalyzing the conversion of 3-phosphoglycerate to 3-phosphohydroxypyruvate. Serine synthesis is crucial for macromolecule synthesis, neutralizing oxidative stress, and regulating methylation reactions. This pathway is associated with various biological processes such as cell proliferation, metastasis, and immune-related functions [1,3,4,6].
In bladder cancer, knockdown of Phgdh promoted ferroptosis and decreased cancer cell proliferation while downregulating SLC7A11 expression. Phgdh interacts with PCBP2, inhibiting its ubiquitination degradation, and PCBP2 in turn stabilizes SLC7A11 mRNA [1]. In breast cancer, loss of Phgdh potentiated metastatic dissemination, with low Phgdh expression in primary tumors associated with decreased metastasis-free survival. Mechanistically, loss of the interaction between Phgdh and phosphofructokinase activated the hexosamine-sialic acid pathway, leading to aberrant protein glycosylation and increased cell migration [2]. In hepatocellular carcinoma, PRMT1-mediated methylation of Phgdh at arginine 236 enhanced its catalytic activity, promoting serine synthesis and tumor growth. Blocking this methylation inhibited serine synthesis and restrained tumor growth [4]. In glioblastoma, genetic ablation of Phgdh in endothelial cells pruned over-sprouting vasculature, abrogated intratumoral hypoxia, and improved T-cell infiltration. In HCC, inactivation of Phgdh reduced the production of key metabolites, elevated ROS levels, and induced apoptosis upon Sorafenib treatment. The Phgdh inhibitor NCT-503 worked synergistically with Sorafenib to abolish HCC growth. In pre-clinical models of brain metastasis, genetic suppression and pharmacologic inhibition of Phgdh attenuated brain metastasis but not extracranial tumor growth [5,7,8].
In conclusion, Phgdh plays a vital role in serine synthesis, which impacts multiple biological processes and disease conditions. Gene knockout and other loss-of-function models have revealed its significance in cancer metastasis, tumor growth, and response to therapies in various cancers, highlighting its potential as a therapeutic target [1-2,4-5,9-10].
References:
1. Shen, Liliang, Zhang, Junfeng, Zheng, Zongtai, Zhang, Wentao, Yao, Xudong. 2022. PHGDH Inhibits Ferroptosis and Promotes Malignant Progression by Upregulating SLC7A11 in Bladder Cancer. In International journal of biological sciences, 18, 5459-5474. doi:10.7150/ijbs.74546. https://pubmed.ncbi.nlm.nih.gov/36147463/
2. Rossi, Matteo, Altea-Manzano, Patricia, Demicco, Margherita, Rheenen, Jacco van, Fendt, Sarah-Maria. 2022. PHGDH heterogeneity potentiates cancer cell dissemination and metastasis. In Nature, 605, 747-753. doi:10.1038/s41586-022-04758-2. https://pubmed.ncbi.nlm.nih.gov/35585241/
3. Cai, Zhengnan, Li, Wan, Hager, Sonja, Heffeter, Petra, Weckwerth, Wolfram. 2024. Targeting PHGDH reverses the immunosuppressive phenotype of tumor-associated macrophages through α-ketoglutarate and mTORC1 signaling. In Cellular & molecular immunology, 21, 448-465. doi:10.1038/s41423-024-01134-0. https://pubmed.ncbi.nlm.nih.gov/38409249/
4. Wang, Kui, Luo, Li, Fu, Shuyue, Wei, Xiawei, Huang, Canhua. 2023. PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma. In Nature communications, 14, 1011. doi:10.1038/s41467-023-36708-5. https://pubmed.ncbi.nlm.nih.gov/36823188/
5. Zhang, Duo, Li, Albert M, Hu, Guanghui, Gong, Yanqing, Fan, Yi. 2023. PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy. In Cell metabolism, 35, 517-534.e8. doi:10.1016/j.cmet.2023.01.010. https://pubmed.ncbi.nlm.nih.gov/36804058/
6. Lee, Chae Min, Hwang, Yeseong, Kim, Minki, Kim, Hyeonhui, Fang, Sungsoon. 2024. PHGDH: a novel therapeutic target in cancer. In Experimental & molecular medicine, 56, 1513-1522. doi:10.1038/s12276-024-01268-1. https://pubmed.ncbi.nlm.nih.gov/38945960/
7. Wei, Lai, Lee, Derek, Law, Cheuk-Ting, Wong, Carmen Chak-Lui, Wong, Chun-Ming. 2019. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. In Nature communications, 10, 4681. doi:10.1038/s41467-019-12606-7. https://pubmed.ncbi.nlm.nih.gov/31615983/
8. Ngo, Bryan, Kim, Eugenie, Osorio-Vasquez, Victoria, Cantley, Lewis C, Pacold, Michael E. 2020. Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. In Cancer discovery, 10, 1352-1373. doi:10.1158/2159-8290.CD-19-1228. https://pubmed.ncbi.nlm.nih.gov/32571778/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
